Targets for medical therapy in obesity

Digestive Diseases

Volumn 30, Issue 2, 2012, Pages 168-172

  Baretić, Maja ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Anti obesity drugs; Glucagon like peptide 1; Obesity; Off label products; Side effects; Therapy

Indexed keywords

ANTIOBESITY AGENT; FLUOXETINE; INCRETIN; PHENTERMINE; PLACEBO; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

AMNESIA; ARTERIAL PRESSURE; ARTICLE; BIRTH DEFECT; BLOOD PRESSURE; BODY MASS; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STEATORRHEA; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; HUMANS; OBESITY;

EID: 84862856242     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000336672     Document Type: Article

References (15)

1. Brug J: The European Charter for Counteracting Obesity: a late but important step towards action. Observations on the WHOEurope Ministerial Conference, Istanbul, November 15-17, 2006. Int J Behav Nutr Phys Act 2007; 4: 11.
2. Global Status Report on Noncommunicable Diseases 2010 WHO Headquarters. http://www.who.int/nmh/publications/ncd-report- full-en.pdf.
3. Fister K, Kolcic I, Music Milanovic S, Kern J: The prevalence of overweight, obesity and central obesity in six regions of Croatia: results from the Croatian Adult Health Survey. Coll Antropol 2009; 33: 25-29.
4. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults -The Evidence Report. National Institutes of Health. Obes Res 1998; 6: 51-209.
5. Lesses MF, Myerson A: Benzedrine sulphate as an aid in the treatment of obesity. N Engl J Med 1938; 218: 119-124.
6. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration Guidance for the Clinical Evaluation of Weight-Control Drugs. Crit Rev Food Sci Nutr 2001; 41: 91-94.
7. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
8. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
9. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H: Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004; 27: 1077-1080.
10. Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE clinical guideline 43. www.nice. org.uk/CG04.
11. Barber TM, Begbie H, Levy J: The incretin pathway as a new therapeutic target for obesity. Maturitas 2010; 67: 197-202.
12. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 16: 1341-1352.
13. Wise S: Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992; 55: 181-184.
14. Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S: A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1599-1605.
15. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M: Rapid -ly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391.